Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Tomotaka Kato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-7651-4774; OpenAlex author ID A5112368580. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 9

  1. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  2. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  3. Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. Co-author DOI 10.1007/s00423-023-02942-0↗
  4. New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer during pancreaticoduodenectomy (with video). Co-author DOI 10.1007/s00423-023-03159-x↗
  5. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Co-author DOI 10.3892/ijo.2023.5499↗
  6. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  7. Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with … Co-author DOI 10.1245/s10434-022-11382-x↗
  8. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. First author DOI 10.1038/s41598-021-89530-8↗
  9. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0252917↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Oba · 5 shared papers, 2022–2026 · strength 1.02
  2. Yosuke Inoue · 5 shared papers, 2022–2026 · strength 0.89
  3. Yu Takahashi · 5 shared papers, 2022–2026 · strength 0.89
  4. Hiromichi Ito · 5 shared papers, 2021–2026 · strength 0.89
  5. Yoshihiro Ono · 4 shared papers, 2022–2026 · strength 0.83
  6. Naoki Sasahira · 3 shared papers, 2022–2026 · strength 0.59
  7. Takashi Sasaki · 2 shared papers, 2026 · strength 0.48
  8. Aya Maekawa · 2 shared papers, 2026 · strength 0.48
  9. Masato Ozaka · 2 shared papers, 2026 · strength 0.48
  10. Tatsunori Miyata · 2 shared papers, 2026 · strength 0.48
  11. Masaaki Iwatsuki · 2 shared papers, 2026 · strength 0.48
  12. Hiroaki Ono · 3 shared papers, 2021–2023 · strength 0.40
  13. Kosuke Ogawa · 3 shared papers, 2021–2023 · strength 0.40
  14. Minoru Tanabe · 3 shared papers, 2021–2023 · strength 0.40
  15. Shinji Tanaka · 3 shared papers, 2021–2023 · strength 0.40
  16. Yoshihiro Ono · 2 shared papers, 2022–2023 · strength 0.30
  17. Manabu Takamatsu · 2 shared papers, 2022–2023 · strength 0.30
  18. Yoshiki Murase · 2 shared papers, 2021–2023 · strength 0.27
  19. Shuichi Watanabe · 2 shared papers, 2021–2023 · strength 0.27
  20. Yu Takahashi · 1 shared paper, 2026 · strength 0.24
  21. Yosuke Inoue · 1 shared paper, 2026 · strength 0.24
  22. Toshiro Ogura · 2 shared papers, 2021 · strength 0.24
  23. Daisuke Ban · 2 shared papers, 2021 · strength 0.24
  24. Y. H. Andrew Wu · 1 shared paper, 2023 · strength 0.18
  25. Shoki Sato · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.